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A B S T R A C T
Chronic obstructive pulmonary disease (COPD) is an age and smoking related progressive, pulmonary disorder
presenting with poorly reversible airﬂow limitation as a result of chronic bronchitis and emphysema. The
prevalence, disease burden for the individual, and mortality of COPD continues to increase, whereas no eﬀective
treatment strategies are available. For many years now, a combination of bronchodilators and anti-inﬂammatory
corticosteroids has been most widely used for therapeutic management of patients with persistent COPD.
However, this approach has had disappointing results as a large number of COPD patients are corticosteroid
resistant. In patients with COPD, there is emerging evidence showing aberrant expression of epigenetic marks
such as DNA methylation, histone modiﬁcations and microRNAs in blood, sputum and lung tissue. Therefore,
novel therapeutic approaches may exist using epigenetic therapy. This review aims to describe and summarize
current knowledge of aberrant expression of epigenetic marks in COPD. In addition, tools available for re-
storation of epigenetic marks are described, as well as delivery mechanisms of epigenetic editors to cells.
Targeting epigenetic marks might be a very promising tool for treatment and lung regeneration in COPD in the
future.
1. Introduction
Epigenetics is generally deﬁned as the study of heritable or acquired
mitotically stable changes in gene expression that occur without var-
iation in DNA sequence. Epigenetic marks can be mainly subdivided in
three classes: DNA methylation, post-translational histone modiﬁca-
tions (histone PTMs, including histone acetylation, methylation, phos-
phorylation, ubiquitination and sumoylation) and non-coding RNAs,
with all three probably induced by environmental factors, diet, dis-
eases, and processes involved in ageing (Fraga et al., 2005;
Yang & Schwartz, 2011). All somatic cells in an organism initially have
the same DNA sequence, but somatic mutations accumulate over time,
which contributes to phenotype changes in a variety of diseases
including COPD and lung cancers. In recent years, evidence has in-
creased that epigenetic mechanisms inﬂuence gene expression in
chronic lung diseases, such as asthma and chronic obstructive pul-
monary disease (COPD). As such, epigenetics provides the link between
genetic factors and environmental exposures (Kraussetschmann, Meyer,
Dehmel, & Hylkema, 2015; Yang & Schwartz, 2011).
1.1. DNA methylation
DNA methylation is a process by which methyl groups are added to
cytosine residues in cytosine-phosphate-guanine (CpG) dinucleotides
and catalyzed by DNA methyltransferase (DNMT) family members. The
DNA methylation status is associated with the activity of a DNA
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segment and does not aﬀect the sequence. Generally, DNA hy-
permethylation of CpG islands in gene promoter regions usually leads to
gene silencing, and hypomethylation triggers transcription activation
(Yang & Schwartz, 2011).
1.2. Post-translational histone modiﬁcations
Chromatin is organized into subunits (called nucleosomes), which
consist of a protein octamer, including two copies of each core histone
H2A, H2B, H3 and H4 where 147 bp DNA is wrapped around with, and
the linker H1. Histones are the main protein components of chromatin,
playing an important role in gene regulation. The histone PTMs that
mainly occur on the histone tails form a histone code which can be
deciphered by other proteins. Many studies have established that
H3K4me3 is closely associated with the activation of gene expression,
while H3K9me3 and H3K27me3 are related to gene repression.
1.3. Non-coding RNAs
Non-coding RNAs (ncRNAs) are classiﬁed into four well-character-
ized forms: microRNAs (miRNAs), small interfering RNAs (siRNAs),
Piwi-interacting RNAs (piRNAs) and long non-coding RNAs (LncRNAs)
(Jodar, Selvaraju, Sendler, Diamond, & Krawetz, 2013). miRNAs are
short non-coding RNA molecules containing approximately 22 nucleo-
tides, that negatively regulate gene expression through interacting with
the 3′-UTR (untranslated regions) of mRNA (messenger RNA) which
result in the degradation of mRNA or repression of protein translation
(Bartel, 2004; Flynt & Lai, 2008). For a long time, the main function of
piRNA was thought to be the protection of germ cell genome integrity
by silencing mRNA of transposable elements, which can interrupt the
genome by insertion or transposition (Siomi, Sato, Pezic, & Aravin,
2011). However, recent studies have elucidated additional roles
showing their involvement in genome rearrangement and epigenetic
programming (Ross, Weiner, & Lin, 2014).
1.4. COPD and current treatment
COPD is a progressive disease, characterized by irreversible airway
obstruction, excessive mucus secretion, inﬂammation, extracellular
matrix destruction and abnormal tissue repair (Celli et al., 2004). Ac-
cording to the World Health Organization (WHO), over 200 million
people worldwide suﬀer from COPD, with the incidence increasing with
ageing. The disease is currently the third leading cause of death
worldwide (World Health Statistics, 2008). The most important risk
factor for developing COPD is cigarette smoking, but other inhaled
noxious particles and gases are also recognized for their pathogenic role
(Celli et al., 2004).
Currently, there is no cure for COPD. After diagnosis, the goal of
clinical treatment of COPD is to improve a patient's health status and
quality of life. Aside from smoking cessation being the foremost module
for currently smoking patients (Schamberger, Mise,
Meiners, & Eickelberg, 2014; Willemse et al., 2005), maintenance
therapy with inhaled corticosteroids (IHC) - in combination with long-
acting bronchodilators- have formed a cornerstone for management of
moderate and severe COPD for almost 20 years. In particular patients
with enhanced eosinophilic counts in blood respond well to high doses
of the combination of IHC/long-acting β2-agonist (Pavord et al., 2015).
However, whereas severe asthma patients with high eosinophilic levels
might beneﬁt from anti-eosinophil therapies, including blocking anti-
bodies against IL-5, IL-13 and IL-33 (Barnes, 2015), it yet has to be
proven if these immunotherapeutic treatments are beneﬁcial for (a
subgroup of) COPD patients as well (Barnes, 2015). Regarding patients
with enhanced neutrophilic counts, they seem to beneﬁt from treat-
ments with macrolide antibiotics, which next to their classical anti-
microbial actions could also be due to their anti-inﬂammatory or im-
munomodulatory eﬀects (Ni et al., 2014; Uzun et al., 2014). Moreover,
other sorts of health care including health education on nutrition and
exercise programs are also recommended for a subgroup of patients
with COPD (Deane et al., 2017). COPD can present with diﬀerent
phenotypes, most likely resulting from various molecular endotypes.
Therefore, to further improve treatment of COPD, novel strategies for a
more personalized therapeutic approach are urgently required
(Heaney &Mcgarvey, 2017). Such approaches could arise from the
discovery of new therapeutic targets via genome-wide association stu-
dies (GWAS) and epigenetic studies. The dysregulated expression of
genes in COPD such as FAM13A (Chen et al., 2015; Michael et al.,
2010), CHRNA 3/5, IRES2 and HHIP (Pillai et al., 2009) were dis-
covered through population-based GWAS, which represent potential
target genes for COPD therapy. Until now, the mechanisms altering
COPD pathology are mostly unknown and none of the identiﬁed genes
are speciﬁcally targeted by COPD therapeutic approaches yet. Epige-
netic marks, diﬀerent from genetic mutations, underlie heritable yet
reversible changes in gene expression, which makes epigenetic marks
attractive for targeted therapy. It is hoped that the development of
epigenetic technologies will oﬀer an eﬀective clinical therapy for COPD
in the near future. In the following, we will summarize current litera-
ture about DNA methylation, histone modiﬁcations and non-coding
RNAs in COPD and discuss potential possibilities for epigenetic re-
writing.
2. Epigenetic dysregulation in COPD
2.1. DNA methylation
Cigarette smoking stimulates an inﬂammatory response and in-
creases the production of reactive oxygen species (ROS) in the lung,
which promotes the pathophysiological changes related to COPD and
adds to the risk for development of lung cancer (Adcock,
Caramori, & Barnes, 2011). Indeed, emerging evidence exists that ci-
garette smoking is associated with epigenetic changes in blood cells
(Breitling, Yang, Korn, Burwinkel, & Brenner, 2011; Qiu et al., 2011;
Wan et al., 2012), bronchial epithelium (Belinsky et al., 2002; Buro-
Auriemma et al., 2013; Song, Heijink, et al., 2017), lung tissue (Sundar
et al., 2017) and sputum cells (Belinsky et al., 2002; Sood et al., 2010).
DNA methylation is the epigenetic mark that is analyzed in all epi-
genome-wide association studies (EWASs) investigating epigenetic
dysregulation in smokers, with or without COPD. As high throughput
platforms are available that currently enables the interrogation of over
850,000 (850 K) methylation sites quantitatively across the genome at a
single-nucleotide resolution. These published EWASs, covering 27 K or
450 K methylation sites, have shown a clear association between
smoking and altered DNA methylation patterns for a number of genes,
which are mostly cancer-related (Belinsky et al., 2002; Breitling et al.,
2011; Monick et al., 2012; Wan et al., 2012; Zeilinger et al., 2013). So
far the largest EWAS by Zeilinger, reported in 2013, discovered dif-
ferences in the methylation of 187 CpG sites between current smokers
and never smokers in which, with a few exceptions, active smoking was
associated with reduced methylation levels (Zeilinger et al., 2013).
Interestingly, smoking-related changes in methylation turned out to be
reversible, with intermediate methylation levels among former smokers
compared to current and never smokers (Xu, Jia, Zhang,
Breitling, & Brenner, 2015). This reversibility of DNA methylation, re-
lated to dose and time of smoking exposure, indicates that DNA me-
thylation could be used as a biomarker for COPD (Bojesen, Timpson,
Relton, Smith, & Nordestgaard, 2017; Shenker et al., 2013; Zhang,
Yang, Burwinkel, Breitling, & Brenner, 2014; Zhang, Yang, Burwinkel,
Breitling, Holleczek, et al., 2014). Two recent studies in a Korean COPD
cohort conﬁrmed previous ﬁndings identiﬁed in Caucasians but also
discovered novel smoking associated DNA methylation changes in
blood (Lee, Hong, Kim, Kim, & London, 2017; Lee, Hong, Kim,
London, & Kim, 2016). These methylation changes correlated with
smoking intensity and history. Furthermore, diﬀerential methylation
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could be associated with expression proﬁles of corresponding genes in
COPD lung tissues, supporting a possible epigenetic role in the control
of lung function (Lee et al., 2017).
The use of DNA methylation proﬁles in peripheral blood as a bio-
marker for risk of disease and response to therapy, is an attractive
concept as it could be translated into clinical practice with relative ease.
Even more interesting is that identiﬁed smoking-related diﬀerential
methylation signals in peripheral blood were also shown to inﬂuence
risk for development of COPD and lung function (Lee et al., 2017;
Machin et al., 2017; Qiu et al., 2011; Sood et al., 2010; Wielscher et al.,
2015). One result of interest would be hypomethylation of CpG site
cg02181506 in the SERPINA1 gene on chromosome 14, which was as-
sociated with COPD (Qiu et al., 2011). However, all these reports in
peripheral blood were based on cross sectional analyses of DNA me-
thylation and lung function, and there are no consistent ﬁndings across
the identiﬁed studies, possibly due to the heterogeneity of methods
used in the various studies (Machin et al., 2017).
In sputum, aberrant promoter methylation of the p16 or GATA4
genes was found to be associated with low lung function and increased
odds of COPD among smokers (Meek, Sood, Petersen,
Belinsky, & Tesfaigzi, 2015; Sood et al., 2010). Furthermore, airway
GATA4 gene methylation status may also independently predict health
status in individuals with COPD (Meek et al., 2015). Also, increased
promoter methylation of lung cancer-associated genes, such as SULF2,
was observed in sputum DNA of ex-smokers with persistent chronic
mucous hypersecretion (CMH), which is a clinical phenotype of COPD
(Bruse et al., 2014).
Interestingly, the aberrant DNA methylation parameters which
correlated with COPD also include overexpression of enzymes involved
in DNA methylation: DNA methyltransferase 1 (DNMT1), DNMT3a and
DNMT3b. DNMT1 is the most abundant DNA methyltransferase in
mammalian cells, and is considered to be the key maintenance me-
thyltransferase in mammals (Bayarsaihan, 2011). DNMT3a and
DNMT3b are de novo DNA methylation enzymes. A few publications are
available regarding the correlation between DNMTs and COPD: Liu
reported a reduction of DNMT1 and an augmentation of DNMT3b ex-
pression in normal human small airway epithelial cells and human
bronchial epithelial cells (HBECs) after chronic exposure to cigarette
smoke condensate (CSC) (Liu et al., 2010). Besides that, the genes
D4Z4, NBL2, and LINE-1 repetitive DNA sequences showed a time de-
pendent hypomethylation in HBECs exposed to CSC (Liu et al., 2010).
In addition, hypermethylation of IL-12Rbeta2 and WIF-1 frequently
occurred in the transition of COPD to lung cancer (Suzuki et al., 2010).
However, to understand the consequences of aberrant DNA methylation
in various cell types, future research must include functional studies
investigating (reprogramming of) DNA methylation in speciﬁc cell
types (Song, Cano-Rodriquez, et al., 2017; Song, Heijink, et al., 2017),
which eventually may lead to the discovery of new targets for COPD
therapy.
2.2. Histone modiﬁcations
Histone acetylation and histone deacetylation are critical regulators
of gene transcription (Marwick et al., 2005; Zong, Ouyang, & Chen,
2015). The imbalance of histone acetylation and deacetylation, modify
nucleosomal structure in the transcription of inﬂammatory cytokine
genes, may thus lead to altered gene expression proﬁles in smokers
susceptible to the development of COPD (Szulakowski et al., 2006).
Some years ago, the role of HAT subtypes in the pathology of
cancer, asthma and COPD was suggested (Barnes, Adcock, & Ito, 2005;
Dekker &Haisma, 2009), and it was proposed that speciﬁc inhibitors of
these HAT subtypes (p300, CBP, PCAF and GCN5) are potential targets
for pharmacological research and clinical applications
(Dekker &Haisma, 2009). In addition, histone deacetylase (HDAC) ac-
tivity and expression, especially for HDAC2, was also shown to be de-
creased in specimens of COPD patients (Adenuga, Yao, March,
Seagrave, & Rahman, 2009; Chen et al., 2012; Ito et al., 2001; Ito et al.,
2005). This is of interest as the reduction of HDAC2 activity in patients
with COPD leads to expansion of inﬂammation and corticosteroid re-
sistance (Barnes, 2005). Recently, the eﬀect of the HDAC1-3-selective
inhibitor MS-275 was investigated in a cigarette smoke model in C57Bl/
6 mice. In this model, where mice were exposed to cigarette smoke for 4
consecutive days, MS-275 robustly attenuated expression of in-
ﬂammatory cytokines KC (mouse IL-8), IL-6 and IL-1 beta and neu-
trophil inﬂux in the lungs (Leus et al., 2017). The release of pro-in-
ﬂammatory cytokines relies on the activity of the transcription factor
nuclear factor kappa B (NF-κB), which cooperates with co-activators,
such as p300 and CREB-binding protein (CBP), containing histone
acetyltransferase (HAT) activity, to activate gene transcription (Adcock,
Tsaprouni, Bhavsar, & Ito, 2007; Barnes et al., 2005). The observed anti-
inﬂammatory eﬀect of HDAC inhibitor MS-275 in smoke-exposed mice
was partly attributed to the anti-inﬂammatory cytokine IL-10, which
was highly upregulated in MS-275 treated macrophages (Leus et al.,
2017). In another study, Clarke et al. reported that protein kinase C
(PKC) beta increased TNFα-induced NF-κB transcriptional activity at
the promoter of CCL11 through recruiting p300/CBP-associated factor
and acetylation of histone H4 in human airway smooth muscle cells
(Clarke et al., 2008).
Aside from acetylase and deacetylase, histone methyltransferase
(HMT) and histone demethylase (HDM) play important roles in reg-
ulating histone methylation. Compared with histone acetylation, his-
tone methylation is a little more complicated: methylation of histone
lysine or arginine residues results in distinct and sometimes even op-
posite functional outcomes. In addition, the same lysine residues may
have diﬀerent intensity of methylation (mono-, di- or tri-methylation),
which lead to varied functions (Mosammaparast & Shi, 2010). For ex-
ample, Histone H3 lysine 4 tri-methylation (H3K4me3) is generally
found on active genes while methylations of H3K9 and H3K27 are
closely related to gene repression. Until now, research focusing on the
mechanism of histone methylation in COPD is limited. Andresen et al.
found that the extent of H3K4me3 signiﬁcantly associates with in-
creasing beta-Defensin 1 (DEFB1) mRNA levels, which closely corre-
lates with pathological progression for COPD (Andresen, Günther,
Bullwinkel, Lange, & Heine, 2011). Moreover, Yildirim et al. demon-
strated that the mRNA and protein levels of PRMT2, a protein arginine
methyltransferase, were upregulated in mouse lung tissue when ex-
posed to hypoxia, which is a latent stimulus for COPD (Yildirim et al.,
2006). Overall, histone methylation may be involved in the pathogen-
esis of COPD, and further studies are needed to expose the underlying
mechanisms.
2.3. microRNA
MicroRNA (miRNA) are, so far, the most characterized and well
known family of non-coding RNAs. These are characterized as single
stranded and 21–23 nucleotides in length. To date, 1881 human
miRNAs have been identiﬁed according to (miRBase.org, 2017). After
formation of the RNA-induced silencing complex (RISC) with Argo-
naute proteins, miRNAs bind to the 3′ UTR of target mRNAs. Thereby
they post-transcriptionally regulate the gene expression by inducing
mRNA degradation, destabilization by deadenylation or inhibition of
translation (Filipowicz, Bhattacharyya, & Sonenberg, 2008). The possi-
bility of imperfect base pairings (except for the seed region) in miRNA-
mRNA interactions allows single miRNAs to regulate numerous targets
throughout the genome and thus it is estimated that miRNAs reg-
ulate> 60% of all protein-coding genes in humans (Friedman, Farh,
Burge, & Bartel, 2009). Further, miRNAs tend to address several key
regulatory molecules in signaling pathways, which is why they are
often considered as master regulators of gene expression (Chen, Chen,
Fuh, Juan, & Huang, 2011; Shalgi, Lieber, Oren, & Pilpel, 2007; Zhou,
Ferguson, Chang, & Kluger, 2007). Their expressions is are highly in-
ﬂuenced by the environment, and along this line environmental
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stressors such as air pollution (Bollati et al., 2010) or cigarette smoke
(Marczylo, Amoako, Konje, Gant, &Marczylo, 2012) have been shown
to alter miRNA levels. The resulting altered global target gene expres-
sion might have detrimental eﬀects on cell homeostasis and could
therewith be implicated in the early pathogenesis of various diseases.
This is strengthened by the fact that aberrant miRNA expression has
been associated with many human pathologies (Poy et al., 2004), in-
cluding chronic lung diseases such as asthma (Donaldson et al., 2013;
Jardim, Dailey, Silbajoris, & Diaz-Sanchez, 2012; Solberg et al., 2012;
Williams et al., 2009) or COPD (Akbas, Coskunpinar, Aynacı, Müsteri
Oltulu, & Yildiz, 2012; Chatila et al., 2014; Conickx et al., 2017;
Donaldson et al., 2013; Ezzie et al., 2012; O'Leary et al., 2016;
Pottelberge et al., 2011; Sato et al., 2010; Shen et al., 2017; Soeda et al.,
2013). For example, the expression of let-7c and miR-125b was found to
be decreased in COPD patients compared with healthy subjects. Inter-
estingly, the expression of let-7c target genes such as tumor necrosis
factor receptor type II (TNFRII) was found to be increased in the sputum
of smoking patients with COPD, which was inversely correlated with
the expression of let-7c (Pottelberge et al., 2011). In addition, miR-145
negatively regulates the release of pro-inﬂammatory cytokines from
airway smooth muscle cells in COPD patients by targeting SMAD3, an
important downstream mediator of the transforming growth factor
(TGF)-β pathway (O'Leary et al., 2016). Please read (Osei et al., 2015)
for an extensive review on dysregulated miRNAs in COPD and their
putative implication in disease pathogenesis.
Strikingly, miRNAs do not only regulate normal gene expression but
are more and more implicated in controlling epigenetic mechanisms.
Along this line, the inﬂuence of miRNAs on epigenetics has been ex-
tensively studied in past years and it is well established that there is a
complex interplay between miRNAs with the classical epigenetic ma-
chinery such as DNA methylation and or/histone modiﬁcation. On one
hand, the temporal and spatial expression of miRNA is tightly con-
trolled by epigenetic mechanisms, such as DNA methylation of pro-
moter regions (Xiao et al., 2015), or histone deacetylation (Zhang et al.,
2012) and methylation (Vrba et al., 2010). On the other hand, miRNAs
can also inﬂuence epigenetics by regulating the expression of single
components of the epigenetic machinery such as histone deacetylases or
DNA methyltransferases. Both interactions have been implicated in
many complex human diseases as extensively reviewed elsewhere
(Poddar, Kesharwani, & Datta, 2017). Future studies should address this
complex interplay between miRNAs and epigenetic mechanisms, as
therapeutic targeting of one component will most likely also have an
eﬀect on the other and vice versa.
Additionally, it is now well accepted that miRNAs do not only act in
one particular cell type, but are actively transported within extra-
cellular vesicles (EV). EVs are a family of information-transmitting
nanovesicles, which are secreted by virtually all cell types into the
extracellular space and thus can be isolated from nearly all body ﬂuids
(Mulcahy, Pink, & Carter, 2014). They are divided into diﬀerent sub-
classes according to size and cellular origin: Exosomes are small na-
novesicles (< 100 nm) derived from multivesicular bodies in late en-
dosomes, while larger microvesicles (100 nm−1 μm) are shed from the
plasma membrane. EVs contain a large variety of bioactive molecules
such as proteins, lipids, carbohydrates, and nucleic acids including
small, non-coding RNAs, which can be functionally transfered upon
uptake by target cells (Mittelbrunn et al., 2011). Thereby, the uptake of
EVs is at least in part selectively determined by surface proteins
(Mulcahy et al., 2014). Besides their function in cell homeostasis and
regular cell-cell communication, EVs might also be involved in epige-
netic regulatory mechanisms (Barry, 2013; Cossetti et al., 2014;
Sharma, 2014; Smythies, Edelstein, & Ramachandran, 2014), as they
have been shown to contain components of the epigenetic machinery,
such as HDACs and DNMTs (Beckler et al., 2013; Skogberg et al., 2013).
EVs from embryonic stem cells actively reprogram committed pro-
genitors back to pluripotency (Ratajczak et al., 2006). Thereby the
content of EVs diﬀers in many diseases - which indicates a speciﬁc
sorting of e.g. miRNAs into the vesicles upon injury or cellular stress,
refer to (Mateescu et al., 2017) for a comprehensive review. Secretion
of EVs can also be induced by exposure to cigarette smoke, mainly from
bronchial epithelial cells in the lung (Kadota et al., 2016). These EVs
have been shown to be enriched in pathogenic factors such as the ex-
tracellular matrix - associated protein CCN1 (Moon et al., 2014) but
also miR-210 (Fujita et al., 2015). The latter has been shown to sup-
press autophagy, promote myoﬁbroblast diﬀerentiation and therewith
induce pathological airway remodeling in COPD (Fujita et al., 2015).
Further eﬀects on COPD pathogenesis have been described for EVs se-
creted from macrophages (Cordazzo et al., 2014; Li, Yu,
Williams, & Liu, 2010; Zeitvogel et al., 2012) and mainly microvesicles
derived from endothelial cells (Chironi et al., 2009; Heiss et al., 2008;
Thomashow et al., 2013).
In summary, cigarette smoking and COPD alter the expression, and
most likely also the secretion, of miRNAs into EVs. While it is well es-
tablished that these mechanisms contribute to the development of
airway remodeling and other COPD pathologies, it is intriguing to
speculate that a diﬀerential miRNA sorting into EVs might even be
implicated in systemic distribution of disease risk, i.e. also to the
germline. To our knowledge this has not been investigated in COPD so
far. Thus, EV-mediated transport of small RNAs could be a novel me-
chanism through which environmental inﬂuences on single cells in the
lung could lead to systemic distribution of altered gene expression or
epigenetic marks and future studies should aim to investigate these
underlying mechanisms in detail.
3. Epigenetic editing
Epigenetic editing is an approach to target epigenetic eﬀector do-
mains to any desired gene to rewrite epigenetic marks at a deﬁned locus
(de Groote, Verschure, & Rots, 2012). Many reviews already describe
the status of the ﬁeld demonstrating that rewriting epigenetic marks
modulates gene expression and that even silenced genes in the het-
erochromatin context can be re-expressed using these tools (Cano-
Rodriguez & Rots, 2016; Ecker & Beck, 2017; Falahi, Sgro, & Blancafort,
2015; Sander & Joung, 2014; Tost, 2016). The designed molecular
method mainly includes two constitutes: a DNA targeting system which
can recognize and bind to the speciﬁc sequence in the desired site di-
rectly, and an epigenetic eﬀector domain, which is able to alter the
epigenetic state of the target locus. Up until now, various DNA binding
systems and epigenetic modiﬁers have been applied to activate or re-
press gene expression directly and diﬀerent transfer methods employed
to introduce these agents to the cells (see Fig. 1).
3.1. DNA targeting systems
The DNA targeting systems are designed to bind to the gene of in-
terest with at least nine, but preferably 16 (mathematically unique in
the human genome) base pairs. The DNA targeting platform acts as a
guide to trace its eﬀector domain. Nowadays, three kinds of DNA
binding proteins are widely used. Zinc ﬁnger proteins (ZFPs), the ﬁrst
engineered DNA targeting system, were the ﬁrst to be employed to
regulate the expression of desired genes (de Groote et al., 2014;
Gommans et al., 2007; Huisman et al., 2013; van der Gun et al., 2013).
These early research eﬀorts made use of ZFPs fused to non-catalytic
domains, such as VP16 (a viral transcriptional activator) and its tet-
ramer VP64 or KRAB (a transcriptional repressor)
(Magnenat & Blancafort, 2004; Beltran, Sun, Lizardi, & Blancafort,
2008; Beltran et al., 2011). Later, another programmable gene targeting
protein platform, the Transcription-Activator-Like Eﬀectors (TALEs),
were introduced. However, both ZFPs and TALEs are cumbersome and
resource-consuming to construct, as each newly engineered DNA-
binding protein needs to be fused to the eﬀector domain of interest.
Recently, the Clustered Regularly Interspaced Short Palindromic Re-
peats (CRISPR) and CRISPR-Associated Protein 9 (Cas9) system was
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introduced to target genes of interest in a much more straightforward
manner, which made epigenetic editing available to the broader re-
search community. CRISPR/Cas9 system comprises a single guide RNA
(sgRNA) and the Cas9 protein (Hsu, Lander, & Zhang, 2014), allowing
ﬂexibility in targeting as one dCas9 fusion can be easily targeted to any
gene of interest by only redesigning the sgRNA instead of constructing
new fusion proteins. These DNA targeting platforms, although mainly
exploited for genome engineering, make it experimentally possible to
reprogram gene expression.
3.1.1. ZFPs
C2H2 type zinc ﬁnger proteins (ZFPs) are the ﬁrst naturally occur-
ring examples of predictable DNA recognition modules detected in
eukaryotes and are part of numerous natural transcription factors
(Wolfe, And, & Pabo, 2000). Zinc ﬁnger (ZF) arrays consist of tandem
repeated ZF elements in which each ﬁnger is composed of about 30
amino acids containing one α-helix and two β-sheets, developing a
coherent platform stabilized by zinc ions. Each ZF unit contains three to
four important amino acids on the surface of the α-helix, which can be
engineered to recognize a speciﬁc DNA triplet (Choo & Klug, 1994).
Stitching engineered ZF domains together results in the recognition of
longer stretches of DNA, which subsequently increase the speciﬁcity of
ZFPs (Gersbach, Gaj, & Iii, 2014). ZF arrays with six or more ZF motifs
stitched together can be employed to recognize 18 base pairs which is
are a mathematically unique address in the human genome. This way,
ZFPs have been explored as a powerful tool to target DNA sequence in
the genome. The ﬁrst constructed ZFP was engineered to repress the
fusion oncogene BCR-ABL (Choo, Sánchezgarcía, & Klug, 1994). Many
engineered ZFPs fused with transcriptional activators or repressors
(artiﬁcial transcriptional factors) have subsequently been reported to
regulate the expression of endogenous genes (de Groote et al., 2012).
The main advantages of the ZFPs are the relatively small size and low
immunogenicity (Falahi et al., 2015; Mussolino et al., 2011), although
they are time-consuming and expensive to generate and, so far, not
highly speciﬁc. Nevertheless, the ﬁrst proof of concept studies on epi-
genetic editing are reported using engineered ZFP-fusions (Chen et al.,
2014; Falahi et al., 2013; Gregory, Mikhaylova, & Fedulov, 2012;
Rivenbark et al., 2012; Siddique et al., 2013; Snowden et al., 2003).
3.1.2. TALEs
Another DNA binding system, the Transcription-Activator-Like
Eﬀectors (TALEs), is derived from plant pathogenic bacteria
(Boch & Bonas, 2010). TALEs consist of tandemly repeated and highly
conserved 34 amino acid sections. The recognition speciﬁcity of TALEs
correlates with amino acids located at 12th and 13th (Gaj & Gersbach,
2013; Sun & Zhao, 2013), a region called the repeat variable di-residues
(RVD). Each RVD distinguishes a single base pair within the DNA-
binding site (HD = C, NI = A, NG = T, NN= G), providing gene tar-
geting. Similar to ZFPs, TALEs modulars are tied together to bind with
adjacent DNA sites. Also TALEs have been fused to epigenetic editors to
successfully modulate transcription through binding to the speciﬁc sites
of the host cell genome (Konermann et al., 2013; Maeder et al., 2013).
The disadvantages of TALE arrays are the extensive identical repeat
sequences hampering construction and immunogenicity.
3.1.3. CRISPR-Cas9
The newest breakthrough genome targeting platform is the CRISPR
system, which has revolutionized molecular biology research
(Sander & Joung, 2014). The CRISPR system was ﬁrst identiﬁed as the
bacterial defense system, and categorized into three diﬀerent types. The
type II CRISPR is the simplest design, mainly consists of two compo-
nents: sgRNAs and the protein Cas9 (Hsu et al., 2014). The sgRNAs
functions in the recognition of a target gene sequence of about 20 bps
upstream of a 5′-NGG-3′ PAM (protospacer adjacent motif) site, which
is essential for binding and cleavage. The nuclease protein Cas9, guided
by a sgRNA to a speciﬁc sequence, cleaves double-stranded DNA re-
sulting in breaks in the invading foreign gene. To regulate gene ex-
pression without altering the DNA sequence, a catalytically deactivated
Cas9 (dead Cas 9, dCas9) has been engineered, which still can bind the
speciﬁc genomic site but is not able to cleave it. This homing device can
then be connected with transcriptional or epigenetic modulators
(Sander & Joung, 2014). The advantage of the CRISPR/dCas system is
Fig. 1. Transference of various DNA binding
systems and epigenetic modiﬁers.
Epigenetic editing is employed to rewrite
epigenetic marks at the target gene of in-
terest. The designed molecular tool mainly
includes two constitutes: a DNA binding
domain (DBD) which can recognize and
bind to the speciﬁc sequence in the desired
site directly, and an epigenetic eﬀector do-
main (ED), which is able to alter the epige-
netic state of the target locus. The manip-
ulation of protein is achieved indirectly by
DNA or mRNA level or directly through
protein deliver, where diﬀerent delivery
methods can be employed.
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that the sgRNA is easy to design and cheap, and the nuclease-dead
dCas9 molecule can be fused to diﬀerent epigenetic modulators, which
only need to be constructed once but can then be used for all targets.
These properties make the CRISPR/Cas9 system be the most promising
and widely used gene targeting platform so far.
3.2. Applications in COPD
Until now, limited reports are available regarding the application of
DNA targeting systems in COPD. The airway mucus hypersecretion is
one of the main contributors to the pathogenesis of COPD. One of the
master regulators of mucus production is SAM-pointed domain-con-
taining Ets-like factor (SPDEF), and silencing its expression likely re-
duces mucus secretion. Recently, we have shown that SPDEF was hy-
pomethylated in bronchial epithelial cells after growth at an air-liquid-
interface (ALI) for 2 weeks, when compared to cells from non-COPD
controls. This was accompanied by increased mRNA expression of
SPDEF and the downstream mucus-related genes MUC5AC and AGR2
(Song, Heijink, et al., 2017). Furthermore, we reported that targeted
silencing of SPDEF, using ZFPs and CRISPR/dCas platforms, successfully
attenuated mucus-related gene expression, further reducing mucus
production in lung epithelial cells (Song, Cano-Rodriquez, et al., 2017).
This indicates that epigenetic downregulation of SPDEF has the po-
tential to generate a stable eﬀect of mucus reduction, which may be a
new therapeutic approach to eventually cure patients with excessive
mucus secretion.
Besides this example, DNA targeting systems have been engineered
and tested in various primary cells. For example, an artiﬁcial tran-
scriptional activator, ZFPs fused to VP64, was designed to bind the γ-
globin gene promoter, to activate the expression of the developmentally
silenced fetal γ-globin in primary human adult erythroblasts (Wilber
et al., 2010). Moreover, designed TALEs fused to DNMT3A or TET1
were constructed to target the promoter region of Ascl1 in neural stem
cells, which altered the methylation state and modulated gene expres-
sion (Lo, Choudhury, Irudayaraj, & Zhou, 2017).
4. Delivery and therapeutic potential of Epigenetic Editing
Programmable epigenetic modiﬁcation with designed DNA tar-
geting platforms could potentiate targeted therapy by treating the
speciﬁc histone and DNA methylation marks that contribute to the
progression of diseases. A primary challenge, however, is the develop-
ment of safe and eﬃcient delivery methods in the lung (see Fig. 2).
4.1. Barriers to lung delivery
Theoretically, epigenetic modiﬁcation of gene expression in the
lung could be accomplished by delivering the epigenetic editor to the
epithelial surface via aerosol, the pulmonary arterial or bronchial ar-
terial systems, or via the pleural surface. Several barriers, however,
have been identiﬁed which hamper successful delivery to the lung
(Kim, Duncan, Hanes, & Suk, 2016). First, the lung presents several
physical and immune barriers to keep pathogens and particulates out.
This includes the mucociliary clearance system, tight junctions between
epithelial cells, and alveolar macrophages which will rapidly take up
delivery vehicles, preventing access to the diseased cells. In addition,
excessive mucus production and inﬂammation, which are common in
asthma and COPD, will further exacerbate this challenge to successful
delivery. For targeted delivery, the delivery vehicle must reach and
bind its bona ﬁde receptor in the polarized epithelial cells, while
avoiding binding to the abundant low-aﬃnity receptors present on the
mucus glycocalyx. Additionally, delivery vectors may be inactivated by
the adaptive immune responses, including both neutralizing antibodies
and cytotoxic T lymphocytes, particularly after repeated administra-
tion. Especially for the viral vectors, pre-existing immunity of the host
to viral vectors can also act as a barrier to eﬃcient vector delivery.
Tackling these barriers has led to the development of a range of gene/
protein transfer systems.
4.2. Gene transfer with viral and non-viral vectors
Gene transfer has been widely explored in the lung and based on a
number of studies, viral vectors tend to be more eﬃcient than a non-
viral vector. Especially, modiﬁed viruses with airway cell tropisms have
shown some extent of success, even in the clinical setting (Sondhi,
Stiles, De, & Crystal, 2017).
4.2.1. Retroviral vectors
Retroviruses, including lentiviruses, are RNA-based, and can be
converted to double stranded DNA in host cells, which can then be
integrated into random sites of the host genome. Genomic integration
could be beneﬁcial because of persistent expression of the transgene,
but could also be a risk factor due to potential genotoxicity. Moreover,
retroviruses infect actively proliferating cells only and have therefore
limited application for in vivo lung gene therapy, as in the lung, the vast
majority of cells has been terminally diﬀerentiated and the rate of
proliferating cells is low. This problem has been overcome in part by
lentiviral vectors which are capable of transfecting post-mitotic cells
(Naldini et al., 1996). The absence of suitable cellular receptors on the
apical surfaces of lung epithelial cells represents another factor ham-
pering in vivo lung gene therapy. This problem can be partly overcome
by co-administration of reagents which transiently open tight junctions
(Leoni et al., 2015). Alternatively, pseudotyped (lentivial) vectors, such
as those modiﬁed by the addition of novel surface proteins which are
originated from lung tropism viruses (eg. Inﬂuenza, Sendai virus) have
resulted in eﬀective transfections. Indeed, a ﬁrst-in-man lentivirus trial
in patients is under preparation, where a lentiviral vector (simian im-
munodeﬁciency virus, SIV) pseudotyped with the SeV envelope pro-
teins F and HN is being tested to ﬁght cystic ﬁbrosis (Alton et al., 2017).
The researchers ﬁrst showed that F/HN-pseudotyped SIV vector in-
duced lifelong transgene expression in mice (both in the lungs as well as
in the noses) and repeated administration led to a cumulative dose-
related increase in gene expression without toxicity or loss of eﬃcacy
(Mitomo et al., 2010). Further, they found that the eﬃcacy, toxicity and
integration site proﬁle supports further progression towards clinical
trial and pre-existing and acquired immune responses did not interfere
with vector eﬃcacy (Alton et al., 2017). Therefore, these recombinant
lentiviral vectors are promising for the treatment of chronic lung dis-
ease, while further development of these vectors is also necessary, in-
cluding large-scale production and puriﬁcation, and integrated-defec-
tive but eﬃcient vectors.
4.2.2. Adenoviral vectors
Recombinant adenovirus (rAd) vectors, the ﬁrst eﬀective in vivo
gene delivery vectors, are double-stranded DNA-based viruses which
have natural tropism for the respiratory tract (Nemerow& Stewart,
2016). rAd vectors are capable of infecting both proliferating and non-
proliferating cells, do not integrate into the host genome, and result in
highly eﬃcient gene transfer in vivo. rAd vectors can accommodate
larger inserts (up to 8 kb) than adeno-associated viral vectors (up to
5 kb), mediate transient but high levels of protein expression, and can
be easily produced at high titers. However, adenoviruses may cause
high immunogenity in vivo because of the capsid, double-stranded DNA
genome, or viral proteins expressed from the vector backbone
(Nayak &Herzog, 2010). Moreover, the basolateral localization of re-
ceptors for Ad vectors limit the eﬀectiveness of Ad vectors in lung
disease therapy. “Helper-dependent” Ad was designed to reduce cel-
lular immunity and to increase the cloning capacity transgene size
through removing many of the viral coding sequences, which resulted
in some successes (Józkowicz & Dulak, 2005; Nayak &Herzog, 2010;
Piccolo & Brunetti-Pierri, 2014; Suzuki et al., 2013). However, at the
same time, these vectors raise a safety risk issue as production and
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contamination of replication competent Ad viruses might occur.
Therefore, the Ad vector is a great platform for in vitro study, but cur-
rently not the preferred choice for lung gene therapy.
4.2.3. Adeno-associated viral vectors
Recombinant adeno-associated virus (rAAV) vectors are DNA
viruses which have not been associated with any human disease. As
such, they have received much attention as gene therapy vectors.
However, AAV is also replication deﬁcient itself, so production and
replication of AAV requires help from genes of helper viruses, including
Ad and herpes simplex virus (HSV). rAAV vectors are capable of
transducing non-dividing quiescent cells and mediate long-term gene
expression in a wide variety of tissues, including skeletal muscle, liver,
central nervous system and retina (Daya & Berns, 2008). Numerous
(> 100) AAV serotypes (natural or created) have been tested with di-
verse tissue tropism, which also help to bypass the pre-existing neu-
tralizing antibodies in the human population. Several AAV serotypes
have been shown to mediate eﬃcient transduction of airway and al-
veolar epithelium. AAV delivery of ZFP- and TALE-based transcrip-
tional regulators has demonstrated promising preclinical results in ex-
perimental animal models of Huntington's and Parkinson's disease. The
recent development of smaller Cas9 systems that are compatible with
AAV is a major advance in the development of CRISPR-Cas9-based gene
therapy. In addition, there is a range of promising approaches to
overcome the limitation imposed by the packaging capacity of AAV
such as the use of dual-vector approaches (Chamberlain,
Riyad, &Weber, 2016). Hung and coworkers successfully made
genomic modiﬁcation in mouse retinal cells with dual AAV-mediated
CRISPR/Cas system in vivo (Hung et al., 2016). So, AAV compatible
CRISPR/Cas systems have the potential to accelerate clinical applica-
tions of (epi)genome engineering, including in lung diseases.
4.2.4. Non-viral gene transfer
Non-viral (synthetic) vectors have been developed to avoid the use
of viruses, thus minimizing the risk of immunogenicity and increasing
the chance of eﬀective repeated administration. In addition, non-viral
vectors overcome the inherent shortcoming of viral vectors, such as
potential genome insertional risks (retrovirus and lentivirus), limited
size of the expression cassette (AAV) and the risk of creating replication
competent viruses (Helper-dependent Ad, AAV). In general, however,
non-viral vectors tend to be less eﬃcient in gene transfer in vivo because
of the paucity of speciﬁc components required for cell entry. Typically,
in non-viral vectors, the therapeutic gene is cloned in plasmid DNA
(pDNA) from bacteria or in vitro transcribed resulting in messenger RNA
(IVT-mRNA), and complexed with cationic lipids or/and polymers to
enhance cell entry. Non-viral vectors have been developed for delivery
of pDNA and short interfering RNA. In addition, this platform has been
largely adopted to delivery of IVT-mRNA due to its attractive feature,
which is the fast onset of protein expression without the need to enter
the nucleus in order to be functional. IVT-mRNA has inherent short-
comings because of its instability and immunogenicity, which have
been substantially overcome by structural modiﬁcations.
Cationic lipids have been the most explored as non-viral vectors for
pDNA and IVT-mRNA transfection so far. They can complex with pDNA
or IVT-mRNA through electrostatic interaction and form lipoplexes
(Rezaee, Oskuee, Nassirli, &Malaekeh-Nikouei, 2016). Strategies to
improve transfection eﬃciency of lipoplexes have focused on im-
proving cellular uptake and endosomal escape via optimization of lipid
formulation (such as shielding the liposome surface with hydrophilic
uncharged polymers polyethylene glycol (PEG)) and incorporating
targeting ligand(s), which also help to reduce nonspeciﬁc binding and
increase the circulation half-life in vivo. Lipofectamine is a good ex-
ample of a commercially available liposomal formulation, which has
good transfection proﬁles for both pDNA and IVT-mRNA but has lim-
ited utility in vivo, partially because of its cellular toxicity. GL67A is
Fig. 2. Diﬀerent systems to deliver epigenetic editors.
rAd = recombinant adenovirus, rAAV = recombinant adeno-associated virus, rLV = recombinant lentiviruses, IVT-mRNA = in vitro transcribed resulting in messenger RNA,
DBD = DNA binding domain, ED = epigenetic eﬀector domain.
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another promising lipid-based formulation, which is considered as the
gold standard in non-viral respiratory gene transfer because of its
therapeutic potential, low toxicity and safety proﬁle in many pre-clin-
ical and clinical trials (Alton et al., 2015; McLachlan et al., 2011). Lipid
nanoparticles (LNP) are a class of lipid-like materials. Highly eﬀective
LNPs are composed of a cationic lipid (complexes negatively charged
DNA and RNA and enhances endosomal escape), a naturally-occurring
phospholipid (support lipid bilayer structure), cholesterol (aids in sta-
bility), and lipid PEG derivative (decreases aggregation and nonspeciﬁc
uptake) (Kanasty, Dorkin, Vegas, & Anderson, 2013). Miller and cow-
orkers described the development of the ﬁrst non-viral delivery system
for in vitro and in vivo co-delivery of Cas9 mRNA and targeted sgRNA
from a single LNP (Miller et al., 2017), providing powerful tools for in
vivo gene editing and even epigenetic editing.
Cationic polymers can complex with negatively charged nucleic
acids through charge-charge interaction, forming polyplexes which
normally show higher stability than lipoplexes (Lachelt &Wagner,
2015). Two well-known polymer based carriers are naturally derived
polymer chitosan and synthetic polymer polyethyleneimine (PEI).
Chitosan is considered a biologically safe polymer for controlled de-
livery of DNA, siRNA and IVT-mRNA, in particular to aﬀect local or
systemic delivery of drugs via the body's mucosal barriers because of its
muco-adhesive properties (Mao, Sun, & Kissel, 2010; Okamoto et al.,
2003; Singh et al., 2012). PEI is also commonly used for in vitro and in
vivo lung gene transfer (Davies et al., 2008; Gautam, Densmore,
Golunski, Xu, &Waldrep, 2001; McLachlan et al., 2011). However,
there is also evidence showing that inhaled chitosan microparticles had
signiﬁcant proinﬂammatory eﬀects on lung tissue (Huang, Vieira,
Huang, Yeh, & Chiang, 2005) and PEI can induce widespread immune
cell inﬁltration. Mastorakos and coworkers formulated highly stable
DNA nanoparticles based on biodegradable polymers, poly (β-amino
esters) (PBAEs), possessing a dense coating of PEG, which helps the
DNA nanoparticles to eﬃciently penetrate the mucus gel layer above
the airway epithelium (Mastorakos et al., 2015). Importantly, these
PBAE-based mucus-penetrating DNA nanoparticles (PBAE-MPPs) pro-
vided robust and long term (> 4 month following a single adminis-
tration) transgene expression throughout the mouse lungs, superior to
several gold standard gene delivery systems, including another mucus
penetration polyplex PEGylated PEI/pDNA (Suk et al., 2014), the
conventional polyplex PEGylated PLL/pDNA (Boylan et al., 2012;
Konstan et al., 2004), and a lipoplex GL67A/pDNA (Alton et al., 2015).
Furthermore, the transfection eﬃciency of PBAE-MPPs was not atte-
nuated by repeated administrations, and no signs of toxicity were re-
ported following intratracheal administration. Additionally, Polach
et al., provide an eﬀective delivery of siRNA to the lungs of normal mice
through Staramine modiﬁed with methoxypolyethylene glycol (Star-
amine-mPEG), revealing signiﬁcant target gene knockdown (Polach
et al., 2012; Sparks et al., 2012).
IVT-mRNA and pDNA can also be loaded into hybrid nanoparticles,
which comprise multiple materials (lipids, polymer and peptide) in a
core-shell structure for more potent transfection. Typically, nucleic acid
can be condensed with the “core” (e.g. cationic polymers) or be ab-
sorbed to the surface of the “shell” (liposomes), forming lipopolyplexes
(Rezaee et al., 2016). Additionally, positively charged short peptides
could also be used as “core” components (Lee et al., 2015) and polymer-
based materials as substitutes for “shell” components (Bhavsar & Amiji,
2008; Palama, Cortese, D'Amone, & Gigli, 2015), aiming to optimize the
formulation of the hybrid nanoparticles resulting into eﬃcient trans-
fection with low toxicity. Mahiny and coworkers have successfully
corrected surfactant-B (SP-B) deﬁciency in mouse lungs using intra-
tracheal delivery of ZFP and TALE nuclease-encoding mRNA complexed
with chitosan-coated nanoparticles (Mahiny et al., 2015). This ﬁnding
supports the possibility of using a biodegradable carrier with modiﬁed
mRNA in lung disease therapy by providing a transient pulse of protein
expression, as an alternative to traditional viral vectors.
Subsequently, both the expression level and persistence in the lung
can be improved by optimization of the IVT-mRNA and pDNA mole-
cule. Removal of CG dinucleotides from the transgene and improved
vector design, including careful selection of the promoter/enhancer,
resulted in non-viral vectors with persistent gene expression and a
minimal immune response in mouse lung models (Bazzani et al., 2016;
Padegimas et al., 2012). Modiﬁcation of structural elements and nu-
cleotides of the IVT-mRNA substantially improved its intracellular
stability and translational eﬃciency, and reduced its immunogenicity
(Guan & Rosenecker, 2017).
4.3. Protein delivery
The transient nature of therapeutic protein delivery makes it an
attractive method for delivery of (epi) genome-editing proteins, for
which advantages include (a) no risk of insertional mutagenesis (viral
vector or pDNA) and (b) fewer oﬀ-target events due to reduced ex-
posure time of the (epi)genetic editor within the cell. However, various
challenges exist preventing eﬃcient delivery of (epi)genetic-editing
proteins which obstructs the in vivo application. These challenges in-
clude the large size, structural complexity, proteolytic instability, poor
membrane permeability and endosomal entrapment (ineﬃcient re-
lease) of the proteins. To tackle these challenges, a range of strategies
have emerged in the last few years, including cell-penetrating peptides,
virus-like particles, supercharged proteins, nanocarriers, polymers, and
nanoparticle-stabilized nanocapsules (Fu, Tang, Hardie,
Farkas, & Rotello, 2014). A pulmonary protein delivery system with
microencapsulated chitosan nanoparticles has proven promising for
systematic disease therapy (Al-Qadi, Grenha, Carrión-Recio,
Seijo, & Remuñán-López, 2012) but also for local therapy in lung dis-
eases. Furthermore, Barbas et al. explored the intrinsic cell-penetration
properties of ZFPs and further improved the cell permeability by in-
corporation of tandem nuclear localization signal (NLS) repeats into the
ZFP backbone. Direct protein administration of the constructs in
mammalian cells resulted in eﬃcient genome modiﬁcations, with re-
duced oﬀ-target eﬀects (Gaj, Guo, Kato, Sirk, & Barbas, 2012; Liu, Gaj,
Wallen, & Barbas, 2015). Additionally, the cellular uptake of ZFN pro-
teins can be promoted by transferrin receptor-mediated endocytosis,
facilitating genome editing in varieties of mammalian cells (Chen et al.,
2013). Direct fusion to cell-penetrating TAT peptide (Ru et al., 2013;
Wadia, Stan, & Dowdy, 2004), or conjugation to cell-penetrating poly-
Arg peptides (Liu, Gaj, Patterson, Sirk, & Barbas Iii, 2014) facilitated
direct TALE protein delivery for genome editing. The same principle is
also applicable for gene disruption by cell-penetrating peptide-medi-
ated delivery of a Cas9 protein and guide RNA (Ramakrishna et al.,
2014). The Liu and Xu group developed a potent protein delivery
system for genome editing in vitro and in vivo, using bio reducible lipid
nanoparticles (enhancing the endosome escape of protein) complexed
with negatively supercharged Cre recombinase or Cas9:sgRNA com-
plexes (Wang et al., 2016; Zuris et al., 2015).
For genetic editing protein delivery, multiple viral vector systems
have also been explored, like integrase-deﬁcient lentiviral vectors
(IDLVs) (Cai, Bak, &Mikkelsen, 2014; Lombardo et al., 2007), non-in-
tegrating gamma-retroviral vectors (NIRVs) (Bobis-Wozowicz et al.,
2014), adenoviral vectors (AdV), and adeno-associated viral vectors
(AAVs) (Ellis, Hirsch, Porter, Samulski, & Porteus, 2013; Händel et al.,
2012), with higher protein expression and delivery eﬃciency and dis-
tinct cell tropism (especially for AAVs) due to receptor-mediated
transfer. Further improvement is possible when the transduction eﬃ-
ciency is increased and targeting speciﬁcity via modifying the vector
envelope with a cell type speciﬁc ligand or pseudotyping a speciﬁc
trophism glycoprotein.
Bacteria are another emerging protein delivery tool, with the ad-
vantage of being (a) easy to manipulate and adaptable to scaling up and
(b) safe, because the delivery strains can be easily eliminated using
simple antibiotic treatment. The type III secretion system (T3SS) of
Pseudomonas aeruginosa is a powerful tool for direct protein delivery
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into mammalian cells and has successfully been used to deliver various
exogenous proteins into mammalian cells (Hauser, 2009). Recently, the
Jin group employed T3SS-mediated TALEN protein delivery for in-
troducing precise gene modiﬁcation in mouse and embryonic stem cells
(ESCs) and human induced pluripotent stem cells (hiPSCs) with high
eﬃciency (Jia et al., 2015). Importantly, the T3SS system was recently
reengineered within a nonpathogenic strain of Escherichia coli (E. coli)
with a safer proﬁle, which will provide a highly ﬂexible protein de-
livery platform with potential for future therapeutic applications
(Reeves et al., 2015). Back in 2008, a genetically modiﬁed E. coli was
already used as a gene therapy carrier for bactofection of lung epithelial
cells in vitro and in vivo (Larsen et al., 2008). Although the bactofection
resulted in signiﬁcantly lower gene expression than cationic lipid GL67-
mediated gene transfer, it is worthwhile to continue to explore the
application potential of T3SS-mediated (epi)genetic editor protein de-
livery using modiﬁed E. coli in lung disease therapy.
Another fascinating method for protein delivery is “iTOP”, induced
transduction by osmocytosis and propanebetaine, which is reported by
the Geijsen group (D'Astolfo et al., 2015). iTOP allows highly eﬃcient
delivery of native proteins, independent of any transduction peptide,
including both recombinant cytoplasmic and nuclear proteins, into a
wide variety of primary cell types. The underlying mechanism of iTOP
is an active process mediated by hyperosmolality caused by NaCl, in
combination with a transduction compound (propanebetaine), trig-
gering macropinocytotic uptake and intracellular release of extra-
cellularly applied macromolecules. iTOP has proved to be a highly ef-
ﬁcient and non-integrative manner for in vitro delivery of recombinant
Cas9 protein and in-vitro-transcribed sgRNA, which opens a new ther-
apeutic avenue for potential protein delivery of (epi)genetic editors in
lung disease therapy.
4.4. miRNA delivery
Being master regulators of gene expression and given their potential
to regulate the epigenetic machinery, targeting miRNAs has been pro-
posed for therapy of several complex diseases (Collison, Mattes,
Plank, & Foster, 2011; Lu, Munitz, & Rothenberg, 2009; Mattes,
Collison, Plank, Phipps, & Foster, 2009; Polikepahad et al., 2010).
Current approaches to either therapeutically silence by antagomiRs or
induce distinct miRNAs by miRNA mimics is extensively reviewed in
(Comer, Ba, Singer, & Gerthoﬀer, 2014) and will not be discussed in
detail here. There are two major problems that miRNA-based ther-
apeutic approaches face: ﬁrst, as discussed earlier, single miRNAs have
numerous targets throughout the genome thus global induction or si-
lencing might result in huge side eﬀects. Second, eﬃcient and non-
immunogenic application of small single-stranded RNA requires in-
tensive chemical modiﬁcation or complex delivery systems such as viral
or non-viral lipid based delivery systems (Lin, Chen, Zhang, & Zheng,
2014; Martin & Caplen, 2007). It can be imagined that speciﬁc and ef-
ﬁcient delivery becomes even more diﬃcult when targeting diseased
tissue, such as small airways in COPD with massive mucus production.
Strategies to use artiﬁcially designed nanoparticles seem promising,
however these particles still cause high hepatotoxicity due to accumu-
lation in the liver (Volkovova et al., 2013). In order to circumvent these
problems, it has recently been suggested to exploit the natural route of
(miRNA) delivery to cells, the extracellular vesicles (Alvarez-Erviti
et al., 2011; Koppers-Lalic, Hogenboom, Middeldorp, & Pegtel, 2013;
Zitvogel et al., 1998). Due to their cellular origin and natural function,
EVs have a comparable membrane structure to cells, conserving their
lipid composition, ﬂuidity, and membrane proteins and they usually
carry the uptake machinery with them, which is an advantage over li-
posomes and increases their stability in vivo (Ohno,
Drummen, & Kuroda, 2016). There are several encouraging studies in
animal models that EVs might be a useful tool to deliver small RNAs. In
a hallmark study, targeted, autologous exosomes expressing a neuro-
tropic protein (RVG peptide) on their surface have been shown to cross
the blood-brain-barrier to deliver siRNA speciﬁcally to neurons in mice
(Alvarez-Erviti et al., 2011). In this study, small RNAs were loaded into
EVs by electroporation, but saponin treatment, use of porphyrins and
genetic manipulation of parent cells have also been described as suc-
cessful means to load desired content into EVs (Ohno et al., 2016).
Ohno and colleagues have successfully delivered the let-7a tumor
suppressor miRNA to EGFR positive breast cancer cells via EVs ex-
pressing the GE11 ligand for EGFR, which inhibited tumor growth
(Ohno et al., 2013). Additionally, one study has provided evidence for
successful and functional delivery of inhibitors and mimics of miR-155
to macrophages (Momenheravi, Bala, Bukong, & Szabo, 2014).
Due to these promising results in animal models, the safety and
feasibility of using EVs in human diseases has already been assessed in
several phase I trials on cancer, please see (Shin-Ichiro,
Drummen, &Masahiko, 2016) for a comprehensive review. Brieﬂy
summarized, clinical trials showed the feasibility of large-scale EV-
production and the administration of autologous EVs did not result in
severe side eﬀects or serious toxicity. Even though these results are
highly encouraging, development of EV-based therapeutics should be
handled with care. There are still some uncertainties i.e. regarding the
content, the role in disease development, and the regulation of loading
or secretion of EVs, that are essential to be understood in detail before
exploiting EVs as therapeutic shuttles. Nonetheless, in the future, EVs
might be important tools to deliberately deliver epigenetic modiﬁers
such as miRNAs to target cells and to rewrite unfortunate epigenetic
marks.
4.5. Administration strategies for treatment of lung diseases
For treatment of asthma and COPD, the routes of drug administra-
tion to the lungs are through inhalation or the bloodstream. Airside
delivery of therapeutics to the lungs can be achieved via nasal in-
stillation, intratracheal aerosolization, endobronchial spray or neb-
ulization. Airside delivery has the advantage of preferential accumu-
lation of drugs locally in the lungs, limiting penetration of therapeutics
into the blood circulation with adverse eﬀects for other organs. The
therapeutic eﬃcacy of inhaled drugs is continuously enhanced with the
development of nanotechnology approaches (Kuzmov &Minko, 2015),
which also improve the sustainability of drug release (Loira-Pastoriza,
Todoroﬀ, & Vanbever, 2014). Systemic delivery of therapeutics to the
pulmonary vasculature and the pulmonary epithelial cells is achieved
via intravenous administration of the drug, bearing the limitation of a
short half-life of drugs in the blood stream and low accumulation and
retention in the lungs. Therefore, the success of blood-based treatment
for COPD will require more eﬃcient systemic delivery methods. Sys-
temic transport of protein or ncRNAs to the lungs could be achieved by
using EVs that are homed to the lung, as they are stable in the blood-
stream, usually non-immunogenic, and bear the potential to speciﬁcally
target to distinct populations of lung cells when using speciﬁc receptors.
5. Future perspectives
Current developments in the ﬁeld of epigenetic targeting technol-
ogies bear great promise for the treatment of complex diseases without
clearly deﬁned underlying mutation. The CRISPR/dCas9 technology in
particular, which guides epigenetic enzymes to deﬁned genomic loci to
change DNA methylation or histone methylation and acetylation status
for potentially sustained reprogramming holds the promise to develop
novel therapies for COPD to prevent progressive pulmonary deteriora-
tion. Nonetheless, several important knowledge gaps have to be ad-
dressed to fully proceed into clinical applications.
First of all, COPD is a heterogeneous disease, potentially requiring
precision medicine approaches. Thus biomarkers - which could be
based on epigenetic marks - need to be developed to identify which
epigenetic marks will have to be edited and in what patient groups. As
diﬀerent epigenetic marks have a diﬀerent stability, epigenome based
D.-D. Wu et al. Pharmacology and Therapeutics 182 (2018) 1–14
9
biomarkers would ideally give information which patients will show a
sustained therapy response and who will require continuous treatment.
To proceed into biomarker development, serial EWAS are urgently
needed to obtain information on the kinetics and persistence of epige-
netic marks in various cell types. Second, suitable delivery systems have
to be advanced and routes of drug administration need to be explored.
As discussed above, targeted delivery to the lung might avoid systemic
side eﬀects, but could be prevented by excessive mucus production
hampering access to the cells of interest. One approach might be the
systemic application of EVs, that hold great potential due to their nat-
ural origin, their capacity to be packaged with either small RNAs but
also proteins and the possibility to speciﬁcally target them to certain
cell types. However, the detailed targeting mechanism of single EVs
needs to be further understood and suitable surface markers for a
highly-speciﬁc targeting to e.g. lung cells need to be identiﬁed. Thus,
third, it needs to be clariﬁed whether or not it will be necessary to
target speciﬁc cell types and if so which, and how speciﬁcity can be
ensured. Fourth, so far for most epigenetic marks associated with dis-
eases such as COPD, it is not known if they are cause or consequence to
the disease pathogenesis and thus, if correction of those marks will have
a therapeutic eﬀect. It is therefore of utmost importance for future
studies to identify which kind of epigenetic marks are truly relevant for
COPD pathogenesis, and which type of epigenetic modiﬁer is most
suitable to be transferred, i.e. DNMTs/HDACs/miRNAs/miRNA in-
hibitors or mimics, to improve the disease outcome. Furthermore, even
though epigenetic editing promises to stably reprogram gene expres-
sion, more research is needed to fully understand the inﬂuence of native
chromatin environment. In this respect, we recently reported the im-
pact of DNA methylation on sustained re-expression of epigenetic si-
lenced genes (Cano-Rodriguez et al., 2016). Also for SPDEF, a COPD
target, long-term repression could be obtained (Song, Cano-Rodriquez,
et al., 2017). Future work will hopefully overcome these critical hurdles
and reveal if the approach of epigenome editing fulﬁlls its great promise
for clinical applications.
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